menu
    • menu

    Company profile for F2G Limited

    NEW Drugs in Dev: 4
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    F2G is a world-leading UK and Austrian based Biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides, active against Aspergillus and other rare and resistant moulds, that act via a completely different mechanism than currently marketed agents. A Phase IIb O...
    F2G is a world-leading UK and Austrian based Biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides, active against Aspergillus and other rare and resistant moulds, that act via a completely different mechanism than currently marketed agents. A Phase IIb Open Label study is currently ongoing focussing on invasive aspergillosis, scedosporiosis and other rare and resistant mould infections.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    F2G Limitedunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    F2G Ltd Lankro Way Eccles Manchester M30 0LX
    Telephone
    Telephone
    44 (0)161 785 1270
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://f2g.com//
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    F2G Publishes Positive Ph2b Olorofim Data in The Lancet
    F2G Publishes Positive Ph2b Olorofim Data in The Lancet

    18 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/18/3101340/0/en/F2G-Announces-Publication-in-The-Lancet-Infectious-Diseases-of-Phase-2b-Data-Demonstrating-Positive-Therapeutic-Responses-in-Patients-with-Serious-Invasive-Fungal-Diseases-Treated-.html

    GLOBENEWSWIRE
    18 Jun 2025
    Share Share
    F2G Secures $100M For Olorofim Development And Commercialization
    F2G Secures $100M For Olorofim Development And Commercialization

    12 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/12/2945064/0/en/F2G-Announces-100-Million-Financing-to-Advance-Late-Stage-Development-and-Commercialization-of-Novel-Antifungal-Drug-Candidate-Olorofim-in-the-US.html

    GLOBENEWSWIRE
    12 Sep 2024
    Share Share
    F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at TIMM
    F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at TIMM

    21 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/21/2764291/0/en/F2G-and-Shionogi-Present-Full-Data-Set-from-Pivotal-Phase-2b-Study-at-Trends-in-Medical-Mycology-TIMM-2023-Demonstrating-Positive-Therapeutic-Responses-in-Patients-with-Invasive-Fu.html

    GLOBENEWSWIRE
    21 Oct 2023
    Share Share
    F2G Receives CRL from FDA for New Drug Application for Olorofim
    F2G Receives CRL from FDA for New Drug Application for Olorofim

    20 Jun 2023

    // FINANCE YAHOO

    https://finance.yahoo.com/news/f2g-receives-complete-response-letter-113000837.html

    FINANCE YAHOO
    20 Jun 2023
    Share Share
    F2G Receives CRL from FDA for NDA for Olorofim for The Treatment
    F2G Receives CRL from FDA for NDA for Olorofim for The Treatment

    19 Jun 2023

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/f2g-receives-crl-from-fda-for-nda-for-olorofim-for-the-treatment-14551.pdf

    PRESS RELEASE
    19 Jun 2023
    Share Share
    F2G Announces FDA Filing Acceptance of NDA for Olorofim
    F2G Announces FDA Filing Acceptance of NDA for Olorofim

    19 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/12/19/2575954/0/en/F2G-Announces-FDA-Filing-Acceptance-of-New-Drug-Application-for-Olorofim-for-the-Treatment-of-Invasive-Fungal-Infections.html

    GLOBENEWSWIRE
    19 Dec 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search